A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) (NCT05839041)

🧪 Interventions in This Study

• AVD-104 (DRUG)
• Avacincaptad (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (56 Sites)

Showing the first 25 of 56 sites.

• Associated Retina Consultants — Gilbert, Arizona
• Arizona Retina and Vitreous Consultants — Phoenix, Arizona
• Associated Retina Consultants — Scottsdale, Arizona
• Retina Vitreous Associates Medical Group — Beverly Hills, California
• Macula & Retina Institute — Glendale, California
• Northern California Retina Vitreous Associates — Mountain View, California
• Kaiser Permanente — Riverside, California
• Retinal Consultants Medical Group, Inc. — Sacramento, California
• Retinal Consultants Medical Group — Sacramento, California
• West Coast Retina — San Francisco, California
• RCA: California Retina Consultants — Santa Barbara, California
• Retina Group of New England, PC — Waterford, Connecticut
• Rand Eye Institute — Deerfield Beach, Florida
• Retina Group of Florida — Fort Lauderdale, Florida
• Florida Retina Institute — Orlando, Florida
• Retina Specialty Institute — Pensacola, Florida
• Retina Vitreous Associates of Florida — St. Petersburg, Florida
• Southern Vitreoretinal Associates — Tallahassee, Florida
• Center for Retina & Macular Disease — Winter Haven, Florida
• Southeast Retina Center — Augusta, Georgia
• University Retina and Macula Associates — Chicago, Illinois
• Illinois Retina Associates — Oak Park, Illinois
• Midwest Eye Institute — Indianapolis, Indiana
• Cumberland Valley Retina Consultants — Hagerstown, Maryland
• Ophthalmic Consultants of Boston — Boston, Massachusetts

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Geographic Atrophy of the Macula

• A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD — Beverly Hills, California

Explore by condition: All Geographic Atrophy of the Macula clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.